- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
14 result(s) found for: Mammary Gland.
Displaying page 1 of 1.
| EudraCT Number: 2013-001249-15 | Sponsor Protocol Number: 314-12-401 | Start Date*: 2013-11-07 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Otsuka Novel Products GmbH | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Two-Part Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients with Advanced Cancers that are Poorly Responsive ... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: • Advanced prostate cancer • Advanced epithelial ovarian cancer, advanced squamous cell carcinoma of the cervix, advanced breast cancer, endometrial cancer, and salivary gland cancer that are p... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-000510-59 | Sponsor Protocol Number: 01012014 | Start Date*: 2014-08-11 | |||||||||||
| Sponsor Name:Dept of Plastic Surgery, Breast Surgery & Burns | |||||||||||||
| Full Title: Fat transplantation enriched with ex vivo expanded adipose-derived autologous mesenchymal stem cells in reconstruction of the breast. | |||||||||||||
| Medical condition: The study will include participants with breast hypoplasia (International Classification of Diseases-10: DQ 838A). | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-001016-51 | Sponsor Protocol Number: 05-UTROGEL-01 | Start Date*: 2006-02-28 |
| Sponsor Name:Karolinska Hospital | ||
| Full Title: In vivo effects of transdermal Estradiol+ oral Progesterone vs oral Conjugated Equine Estrogens + MedroxyProgesteroneAcetate on normal human breast cells proliferation: a randomized comparative study | ||
| Medical condition: Menopausal symptoms | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-000885-13 | Sponsor Protocol Number: UC-0105/1303 | Start Date*: 2013-07-31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with metastatic or unresectable locally advanced malignancies harboring specific genomic alterations regarding the biological crizotinib targets, and who are no more amenable to curative t... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-005168-14 | Sponsor Protocol Number: UMCN-AKF11.01 | Start Date*: 2012-05-14 | ||||||||||||||||
| Sponsor Name:Radboud University Nijmegen Medical Centre | ||||||||||||||||||
| Full Title: Lean Body Mass as a determinant of docetaxel pharmacokinetics and toxicity (LEANDOC) | ||||||||||||||||||
| Medical condition: Exposure and toxicity of docetaxel treatment with patients with breast or metastatic castration-resistant prostate carcinoma. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-002667-53 | Sponsor Protocol Number: 213409 | Start Date*: 2021-08-23 | |||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||||||||||||
| Full Title: An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and are Judged by the Investigator to Benefit... | |||||||||||||||||||||||
| Medical condition: advanced ovarian, breast, or prostate cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: AT (Trial now transitioned) DK (Completed) ES (Ongoing) IT (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2010-022278-15 | Sponsor Protocol Number: D0810C00042 | Start Date*: 2010-10-25 | ||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||
| Full Title: A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy And Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have A Confir... | ||||||||||||||||||||||||||||
| Medical condition: Patients With Advanced Cancers Who Have A Confirmed Genetic BRCA1 And/Or BRCA2 Mutation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) SE (Ongoing) ES (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2019-004730-42 | Sponsor Protocol Number: IQVIA-ODYS-001-LZA45541 | Start Date*: 2022-10-24 | |||||||||||||||||||||||||||||||
| Sponsor Name:IQVIA RDS FRANCE SAS | |||||||||||||||||||||||||||||||||
| Full Title: Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in c... | |||||||||||||||||||||||||||||||||
| Medical condition: Long term potential effect of repeated exposure to either a linear or a macrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 in motor and cognitive function among ne... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: NL (Ongoing) IT (Ongoing) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-006227-17 | Sponsor Protocol Number: D8410C00001 | Start Date*: 2022-09-14 | |||||||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||||||||||||
| Full Title: A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy an... | |||||||||||||||||||||||||||||||||
| Medical condition: Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D Mdoule 2:... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: SE (Ongoing) ES (Ongoing) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-003432-37 | Sponsor Protocol Number: A005D-E01-201 | Start Date*: 2018-02-06 | |||||||||||||||||||||||||||||||
| Sponsor Name:Advanced Accelerator Applications International SA | |||||||||||||||||||||||||||||||||
| Full Title: Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor | |||||||||||||||||||||||||||||||||
| Medical condition: Malignancies known to overexpress Gastrin-Releasing Peptide Receptors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: AT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-004398-28 | Sponsor Protocol Number: AA01 | Start Date*: 2016-06-17 | ||||||||||||||||||||||||||
| Sponsor Name:Medical Research Council Clinical Trials Unit at UCL [...] | ||||||||||||||||||||||||||||
| Full Title: A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. | ||||||||||||||||||||||||||||
| Medical condition: Cancer (breast, colorectal, gastro-oesophageal and prostate) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IE (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2019-003777-26 | Sponsor Protocol Number: D0817C00098 | Start Date*: 2020-05-27 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||||||||||||
| Full Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment | ||||||||||||||||||||||||||||||||||||||
| Medical condition: BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BG (Ongoing) HU (Ongoing) PL (Ongoing) CZ (Ongoing) ES (Ongoing) DE (Ongoing) IT (Ongoing) DK (Completed) BE (Ongoing) SE (Ongoing) FI (Completed) PT (Ongoing) SI (Ongoing) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-004426-10 | Sponsor Protocol Number: MO28072 | Start Date*: 2012-05-11 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with cancers (excluding melanoma and papillary thyroid cancer) harboring BRAF V600 mutations as identified by the routinely performed mutation analysis assays at each individual partici... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) ES (Completed) DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-001699-39 | Sponsor Protocol Number: HER117158 | Start Date*: 2015-03-11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research Development Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with adva... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Subjects with advanced HER3-positive solid tumors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
